Baudax Bio Inc. [NASDAQ: BXRX] plunged by -$0.06 during the normal trading session on Thursday and reaching a high of $1.58 during the day while it closed the day at $1.45. The company report on March 10, 2021 that Baudax Bio to Participate at the Oppenheimer 31st Annual Healthcare Conference.
Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, announced that Gerri Henwood, President and Chief Executive Officer, will participate in a fireside chat at the virtual Oppenheimer 31st Annual Healthcare Conference on Thursday, March 18, 2021 at 9:20 a.m. ET.
A live webcast of the fireside chat will be available on the “Presentations” page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. A replay will be made available for a period of 30 days following the event.
Baudax Bio Inc. stock has also gained 5.84% of its value over the past 7 days. However, BXRX stock has inclined by 38.10% in the 3 months of the year. Over the past six months meanwhile, it has lost -57.35% and gained 43.56% year-on date.
The market cap for BXRX stock reached $99.53 million, with 70.14 million shares outstanding and 62.71 million shares in the current float. Compared to the average trading volume of 6.20M shares, BXRX reached a trading volume of 4479668 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Baudax Bio Inc. [BXRX]:
JMP Securities have made an estimate for Baudax Bio Inc. shares, keeping their opinion on the stock as Mkt Outperform, with their previous recommendation back on May 15, 2020.
The Average True Range (ATR) for Baudax Bio Inc. is set at 0.17, with the Price to Sales ratio for BXRX stock in the period of the last 12 months amounting to 199.06.
BXRX stock trade performance evaluation
Baudax Bio Inc. [BXRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.84. With this latest performance, BXRX shares dropped by -13.69% in over the last four-week period, additionally sinking by -57.35% over the last 6 months – not to mention a drop of -65.64% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BXRX stock in for the last two-week period is set at 51.93, with the RSI for the last a single of trading hit 54.84, and the three-weeks RSI is set at 51.15 for Baudax Bio Inc. [BXRX]. The present Moving Average for the last 50 days of trading for this stock 1.4563, while it was recorded at 1.4320 for the last single week of trading, and 2.2757 for the last 200 days.
Baudax Bio Inc. [BXRX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Baudax Bio Inc. [BXRX] shares currently have an operating margin of -11319.88 and a Gross Margin at -769.37. Baudax Bio Inc.’s Net Margin is presently recorded at -15436.11.
Reflecting on the efficiency of the workforce at the company, Baudax Bio Inc. [BXRX] managed to generate an average of -$1,335,088 per employee. Receivables Turnover for the company is 19.33 with a Total Asset Turnover recorded at a value of 0.01.Baudax Bio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.90 and a Current Ratio set at 2.00.
Earnings per share (EPS) analysis for Baudax Bio Inc. [BXRX] stock
With the latest financial reports released by the company, Baudax Bio Inc. posted -4.03/share EPS, while the average EPS was predicted by analysts to be reported at -1.79/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -125.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BXRX.
Baudax Bio Inc. [BXRX]: Insider Ownership positions
There are presently around $9 million, or 12.30% of BXRX stock, in the hands of institutional investors. The top three institutional holders of BXRX stocks are: ARMISTICE CAPITAL, LLC with ownership of 3,503,351, which is approximately New of the company’s market cap and around 0.70% of the total institutional ownership; VANGUARD GROUP INC, holding 495,206 shares of the stock with an approximate value of $0.72 million in BXRX stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $0.61 million in BXRX stock with ownership of nearly 1096.034% of the company’s market capitalization.
Positions in Baudax Bio Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 25 institutional holders increased their position in Baudax Bio Inc. [NASDAQ:BXRX] by around 4,953,747 shares. Additionally, 15 investors decreased positions by around 2,011,029 shares, while 6 investors held positions by with 669,069 shares. The mentioned changes placed institutional holdings at 6,295,707 shares, according to the latest SEC report filing. BXRX stock had 13 new institutional investments in for a total of 4,185,881 shares, while 8 institutional investors sold positions of 1,415,368 shares during the same period.